A Phase 3, Open-Label Study to Assess the Long-Term Safety of Dexlansoprazole MR (60 mg QD and 90 mg QD).
Phase of Trial: Phase III
Latest Information Update: 29 Jul 2016
At a glance
- Drugs Dexlansoprazole (Primary)
- Indications Gastro-oesophageal reflux
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda Global Research and Development Center; TAP Pharmaceutical Products
- 19 May 2010 Quality-of-life results presented at Digestive Disease Week 2010.
- 18 Aug 2009 Primary endpoints identified as reported by ClinicalTrials.gov.
- 04 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History